An Innovative Phyto-Supplement Approach for Breast Cancer Supportive Care: Bioresonance-Based Screening Protocol

Background: Breast cancer is the most common malignancy among women worldwide and a leading cause of cancer-related mortality. Despite advances in surgery, chemotherapy, and radiotherapy, complementary therapies—particularly phytotherapy and nutritional interventions—are increasingly used, although their efficacy and safety remain insufficiently validated. Therefore, high-quality scientific evidence is still required to substantiate the use of these approaches. Objective: Based on a comprehensive theoretical review, this study proposes a flexible and integrative research protocol—conceived as an adaptable methodological framework rather than a single fixed trial—to evaluate traditional phytopharmaceutical formulations used in breast cancer, combining molecular, cellular, animal, and clinical approaches with an exploratory bioresonance-based functional screening component. Methods: The protocol integrates device-based exploratory assessment, in vitro, in vivo and clinical modules, providing a multiscale framework to investigate the efficacy, safety, and mechanisms of action of phytotherapeutic interventions. Bioresonance-based measurements are included strictly as exploratory, hypothesis-generating observations, to be cross-validated against established pharmacological, biochemical and clinical endpoints. Expected outcomes: The proposed protocol is expected to combine detailed molecular characterization, functional biological assays and patient-centered clinical monitoring. By integrating preclinical and clinical modules, the framework is intended to support the development of personalized therapeutic strategies and to define how exploratory device-based functional screening can be rigorously evaluated within conventional research pipelines. Conclusions: Overall, this framework may contribute to generating structured evidence on phytotherapeutic strategies and to inform their possible future integration into personalized breast cancer care, provided that its exploratory components are independently validated.